Organization
Department of Urology, Keio University School of Medicine, Tokyo, Japan
2 abstracts
Abstract
Uncovering LAG-3 related tumor immunology in renal cell carcinoma and pan-cancer evaluation.Org: Department of Urology, Nerima General Hospital, Tokyo, Japan, Department of Urology, Keio University School of Medicine, Tokyo, Japan, Department of Urology, Keio University School of Medicine, Shinjuku-Ku, Japan,
Abstract
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.Org: CHRU Besançon Hôpital J.Minjoz, Besançon, France, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, Montreal, QC, Canada, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, Department of Urology, Keio University School of Medicine, Tokyo, Japan, Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil,